Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Staamp Research LLC

Neither a doctor nor a teaching hospital

Research payments

$492,843

829 payments

Through program year 2025, Staamp Research LLC is reported as receiving $492,843 in research payments, across 829 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $161,783 497
2024 Research $55,195 141
2023 Research $84,388 151
2022 Research $72,971 24
2021 Research $29,064 7
2020 Research $89,442 9

Breakdown

Who paid Research payments · program years 2020–2025
  1. Sanofi US Services Inc. $158,127 12 payments
  2. Regeneron Pharmaceuticals, Inc. $86,857 665 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $78,641 127 payments
  4. AstraZeneca Pharmaceuticals LP $67,167 5 payments
  5. GlaxoSmithKline, LLC. $36,484 7 payments
  6. AstraZeneca UK Limited $35,500 2 payments
  7. ALK-Abello, Inc $22,952 6 payments
  8. Genentech, Inc. $3,614 4 payments
  9. Amgen Inc. $3,500 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $78,641 127 payments
  2. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab $72,268 6 payments
  3. Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA) $63,868 240 payments
  4. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab $43,608 1 payment
  5. a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA $37,931 1 payment
  6. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $36,484 7 payments
  7. BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist $26,500 1 payment
  8. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients na $25,051 4 payments
  9. Registry of Asthma Patients Initiating DUPIXENT (RAPID) $22,989 425 payments
  10. Mt-11 $22,952 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record